CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver

Journal of Cellular Physiology

Volumn 226, Issue 9, 2011, Pages 2438-2447

  Cohen, S ^a   Stemmer, S M ^b   Zozulya, G ^a   Ochaion, A ^a   Patoka, R ^a   Barer, F ^a   Bar Yehuda, S ^a   Rath Wolfson, L ^b   Jacobson, K A ^c   Fishman, P ^a  

^a Can Fite BioPharma Ltd   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE RECEPTOR STIMULATING AGENT; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CF 102; FAS LIGAND; GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAD; PROTEIN BAX; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 2 CHLORO N(6) (3 IODOBENZYL) 5' N METHYLCARBOXAMIDOADENOSINE; 2-CHLORO-N(6)-(3-IODOBENZYL)-5'-N-METHYLCARBOXAMIDOADENOSINE; ADENOSINE; ADENOSINE A3 RECEPTOR; ADENOSINE A3 RECEPTOR AGONIST; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; CONCANAVALIN A; DRUG DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CELL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; GROWTH INHIBITION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LIVER; LIVER CELL CARCINOMA; LIVER PROTECTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; DRUG SCREENING; HEPATITIS; LIVER TUMOR; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALIA;

ADENOSINE; ADENOSINE A3 RECEPTOR AGONISTS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CONCANAVALIN A; HEPATITIS; LIVER; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; RECEPTOR, ADENOSINE A3; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79958698872     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22593     Document Type: Article

References (57)

1. 3 adenosine receptor agonists in murine autoimmune arthritis models. J Rheumatol 32: 469-476.
2. Barcz E, Sommer E, Janik P, Marianowski L, Skopinska-Rózewska E. 2000. Adenosine receptor antagonism causes inhibition of angiogenic activity of human ovarian cancer cells. Oncol Rep 7: 1285-1291.
3. 3 adenosine receptor enhances the chemotherapeutic effect of 5-flurouracil in a colon carcinoma murine model. Neoplasia 7: 85-90.
4. 3 adenosine receptor agonists: A novel targeted therapy for rheumatoid arthritis. Expert Opin Investig Drugs 16: 1601-1613.
5. 3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-kappaB signal transduction pathways. Int J Oncol 33: 287-295.
6. Bar-Yehuda S, Rath-Wolfson L, Del Valle L, Ochaion A, Cohen S, Patoka R, Zozulya G, Barer F, Atar E, Piña-Oviedo S, Perez-Liz G, Castel D, Fishman P. 2009. Induction of an antiinflammatory effect and prevention of cartilage damage in rat knee osteoarthritis by CF101 treatment. Arthritis Rheum 60: 3061-3071.
7. 3 adenosine receptor. Circ Res 91: 165-172.
8. Buss H, Dorrie A, Schmitz ML, Frank R, Livingstone M, Resch K, Kracht M. 2004. Phosphorylation of serine 468 by GSK-3beta negatively regulates basal p65 NF-kappaB activity. J Biol Chem 279: 49571-49574.
9. Chan H, Bartos DP, Owen-Schaub LB. 1999. Activation-dependent transcriptional regulation of the human Fas promoter requires NF-kappaB p50-p65 recruitment. Mol Cell Biol 19: 2098-2108.
10. 3 adenosine receptors reduces ischemic brain injury in rodents. J Neurosci Res 84: 1848-1855.
11. Cronstein BN. 1994. Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol 76: 5-13.
12. 3 adenosine receptors decreases heart rate, preserves energetics, and protects ischemic hearts. Am J Physiol 283: 1562-1568.
13. Dugo L, Collin M, Allen DA, Patel NS, Bauer I, Mervaala EM. 2005. GSK 3beta inhibitors attenuate the organ injury/dysfunction caused by endotoxemia in the rat. Crit Care Med 33: 1903-1912.
14. Eigler A, Greten TF, Sinha B, Haslberger C, Sullivan GW, Endres S. 1997. Endogenous adenosine curtails lipopolysaccharide-stimulated tumour necrosis factor synthesis. Scand J Immunol 45: 132-139.
15. Feoktistov I, Ryzhov S, Goldstein AE, Biaggioni I. 2003. Mast cell-mediated stimulation of angiogenesis: Cooperative interaction between A2B and A3 adenosine receptors. Circ Res 92: 485-492.
16. 3 adenosine receptors. J Cell Physiol 183: 393-398.
17. 3 adenosine receptor as a new target for cancer therapy and chemoprotection. Exp Cell Res 269: 230-236.
18. 3 adenosine receptor as a target for cancer therapy. Anticancer Drugs 13: 437-443.
19. Fishman P, Madi L, Bar-Yehuda S, Barer F, Del Valle L, Khalili K. 2002. Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells. Oncogene 21: 4060-4064.
20. 3AR agonist. Anticancer Res 23: 2077-2083.
21. 3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3β and NF-κB. Oncogene 23: 2465-2471.
22. Fishman P, Bar-Yehuda S, Madi L, Rath-Wolfson L, Ochaion A, Cohen S, Baharav E. 2006. The PI3K-NF-kappaB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis. Arthritis Res Ther 8: R33.
23. Gantner F, Leist M, Lohse AW, Germann PG, Tiegs G. 1995. Concanavalin A-induced T-cell-mediated hepatic injury in mice: The role of tumor necrosis factor. Hepatology 21: 190-198.
24. 3 adenosine receptor. J Pharmacol Exp Ther 319: 1200-1210.
25. 3 adenosine receptors for the protective effect of inosine in vivo. Blood 102: 4473-4478.
26. Hanada T, Yoshimura A. 2002. Regulation of cytokine signaling and inflammation. Cytokine Growth Factor Rev 13: 413-421.
27. 3 adenosine receptor agonist potentiates natural killer cell activity. Int J Oncol 23: 1245-1249.
28. Headrick JP, Peart J. 2005. A3 adenosine receptor-mediated protection of the ischemic heart. Vascul Pharmacol 42: 271-279.
29. Jajoo S, Mukherjea D, Watabe K, Ramkumar V. 2009. Adenosine A(3) receptor suppresses prostate cancer metastasis by inhibiting NADPH oxidase activity. Neoplasia 11: 1132-1145.
30. Kaneko Y, Harada M, Kawano T, Yamashita M, Shibata Y, Gejyo F, Nakayama T, Taniguchi M. 2000. Augmentation of Valpha14 NKT cell-mediated cytotoxicity by interleukin 4 in an autocrine mechanism resulting in the development of concanavalin A-induced hepatitis. J Exp Med 191: 105-114.
31. 3 adenosine receptor agonist, in human lung cancer cells. Cancer Lett 264: 309-315.
32. 3 receptor agonists. Biochem Biophys Res Commun 219: 904-910.
33. 3 adenosine receptor activation decreases mortality and renal and hepatic injury in murine septic peritonitis. Am J Physiol Regul Integr Comp Physiol 291: R959-R969.
34. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN, 2000. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343: 1594-1602.
35. Lu J, Pierron A, Ravid K. 2003. An adenosine analogue, IB-MECA, down-regulates estrogen receptor alpha and suppresses human breast cancer cell proliferation. Cancer Res 63: 6413-6423.
36. 6-(3-iodobenzyl)-adenosine-5'-N-methyluronamide, is protective in two murine models of colitis. Eur J Pharmacol 466: 323-329.
37. 3 adenosine receptor activation in melanoma cells: Association between receptor fate and tumor growth inhibition. J Biol Chem 278: 42121-42130.
38. 3 adenosine receptor is highly expressed in tumor versus normal cells: Potential target for tumor growth inhibition. Clin Cancer Res 10: 4472-4479.
39. 3 adenosine receptor in PBMNC of rheumatoid arthritis patients: Involvement of NF-κB in mediating receptor level. J Rheumatol 34: 20-26.
40. 3 adenosine receptors and mitogen-activated protein kinases in lung injury following in vivo reperfusion. Crit Care 10: R65.
41. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Leung E, Maclennan S, Borea PA. 2005. A3 adenosine receptor activation inhibits cell proliferation via phosphatidylinositol 3-kinase/Akt-dependent inhibition of the extracellular signal-regulated kinase 1/2 phosphorylation in A375 human melanoma cells. J Biol Chem 280: 19516-19526.
42. 3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-kappaB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats. Biochem Pharmacol 76: 482-494.
43. 3 adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn's disease. Cell Immunol 258: 115-122.
44. 3 adenosine receptor. J Cell Physiol 186: 19-23.
45. Okano H, Shiraki K, Inoue H, Kawakita T, Yamanaka T, Deguchi M, Sugimoto K, Sakai T, Ohmori S, Fujikawa K, Murata K. 2003. Cellular FLICE/caspase-8-inhibitory protein as a principal regulator of cell death and survival in human hepatocellular carcinoma. Lab Invest 83: 1033-1043.
46. Ougolkov AV, Fernandez-Zapico E, Savoym D, Nrutia RA, Billadeau DD. 2005. Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res 65: 2076-2081.
47. Poulsen SA, Quinn RJ. 1998. Adenosine receptors: New opportunities for future drugs. Bioorg Med Chem 6: 619-641.
48. 3 adenosine receptor agonist prevents bone resorption in rats with adjuvant induced arthritis. Clin Exp Rheumatol 24: 400-406.
49. Schafer DF, Sorrell MF. 1999. Hepatocellular carcinoma. Lancet 353: 1253-1257.
50. 3 receptors in regulation of cardiomyocyte homeostasis after mitochondrial respiratory chain injury. Am J Physiol Heart Circ Physiol 288: H2792-H2801.
51. Sun B, Karin M. 2008. NF-kappaB signaling, liver disease and hepatoprotective agents. Oncogene 27: 6228-6244.
52. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ. 1997. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337: 1029-1035.
53. Tiegs G. 1997. Experimental hepatitis and role of cytokines. Acta Gastroenterol Belg 60: 176-179.
54. Tiegs G, Hentschel J, Wendel A. 1992. A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J Clin Invest 90: 196-203.
55. Whittle BJ, Varga C, Posa A, Molnar A, Collin M, Thiemermann C. 2006. Reduction of experimental colitis in the rat by inhibitors of glycogen synthase kinase-3beta. Br J Pharmacol 147: 575-582.
56. Woodhouse EC, Amanatullah DF, Schetz JA, Liotta LA, Stracke ML, Clair T. 1998. Adenosine receptor mediates motility in human melanoma cells. Biochem Biophys Res Commun 246: 888-894.
57. Xu Z, Jang Y, Mueller RA, Norfleet EA. 2006. IB-MECA and cardioprotection. Cardiovasc Drug Rev 24: 227-238.